Basic Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Nov 15, 2023; 15(11): 1951-1973
Published online Nov 15, 2023. doi: 10.4251/wjgo.v15.i11.1951
Identification of necroptosis-related lncRNAs for prognosis prediction and screening of potential drugs in patients with colorectal cancer
Zhi-Hua Chen, Yi-Lin Lin, Shao-Qin Chen, Xiao-Yu Yang
Zhi-Hua Chen, Shao-Qin Chen, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, Fujian Province, China
Zhi-Hua Chen, Shao-Qin Chen, Department of Gastrointestinal Surgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou 350212, Fujian Province, China
Yi-Lin Lin, Peking University People’s Hospital, Beijing 100044, China.
Xiao-Yu Yang, School of Basic Medicine Sciences, Fujian Medical University, Fuzhou 350122, Fujian Province, China
Author contributions: Chen SQ and Yang XY designed this study; Chen ZH analyzed and wrote the manuscript; Lin YL and Chen ZH analyzed the data and completed the RT-PCR experiment; Chen ZH downloaded the data and performed statistical analysis; All the authors have read and approved the final manuscript.
Supported by the Joint Funds for the Innovation of Science and Technology, Fujian Province, No.2019Y9133.
Institutional review board statement: This data of this article was downloaded CRC RNA-Seq data, clinical follow-up information and copy number variation data from the SNP 6.0 chip in the TCGA database from the UCSC cancer browser , and the Gene Expression Omnibus (GEO) database. This study was approved by the Ethics Committee of the First Affiliated Hospital of Fujian Medical University (NO. MRCTA, ECFAH of FMU[20190(21)]).
Institutional animal care and use committee statement: This artical had not use any animal, so there isnot need any “Institutional Animal Care and Use Committee Approval Form or Document”.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest related to this work.
Data sharing statement: The datasets generated and analyzed during the current study are available in the TCGA repository [https://portal.gdc.cancer.gov/] and the GEO repository [www.ncbi.nlm.nih.gov/geo/]. We declare that the data and materials used to support the findings of this study are provided and included within the supplementary information files.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Yu Yang, PhD, Full professor, School of Basic Medicine Sciences, Fujian Medical University, No. 1 Xuefu North Road, Minhou County, Fuzhou 350122, Fujian Province, China. yxyfj@163.com.
Received: May 16, 2023
Peer-review started: May 16, 2023
First decision: August 7, 2023
Revised: August 15, 2023
Accepted: September 14, 2023
Article in press: September 14, 2023
Published online: November 15, 2023
Processing time: 182 Days and 20.2 Hours
Core Tip

Core Tip: An 8-lncRNA signature significantly associated with overall survival (OS) was constructed, and its fidelity was validated in the OS, disease-specific survival and the progression-free interval, it was also validated with clinical colorectal cancer (CRC) data. The risk score which was correlated with tumor stage, lymph node metastasis and distant metastasis in CRC of the signature showed good concordance with the predicted prognosis. The high-risk group showed greater infiltration of immunosuppressive cells, but fewer infiltrating antitumor effector immune cells. We explored additional potential immune checkpoint genes and immunotherapeutic and chemotherapeutic drugs.